Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology
Care 8 , e001150 (2020)
Metseras portfolio includes: injectable GLP-1 receptor agonist MET-097i (phase 2), amylin analog candidate MET-233i (phase I), two oral GLP-1 RA candidates expected to begin clinical trials imminently, and additional preclinical nutrient-stimulated hormone therapeutics
Savings-card programs generally apply to approved commercial products after launch, not investigational medications still being studied in clinical trials
Individuals with a history of restrictive eating, body dysmorphia, or disordered eating should use GLP-1 medications alongside mental health treatment
